| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 234.73% | Needham | → $8 | Reiterates | Buy → Buy |
| 05/12/2023 | 234.73% | Needham | → $8 | Reiterates | Buy → Buy |
| 04/18/2023 | 234.73% | Needham | → $8 | Reiterates | → Buy |
| 04/12/2023 | 151.05% | B. Riley Securities | → $6 | Initiates Coverage On | → Buy |
| 03/17/2023 | 234.73% | Needham | → $8 | Reiterates | → Buy |
| 03/14/2023 | 192.89% | JonesTrading | → $7 | Initiates Coverage On | → Buy |
| 11/22/2022 | 151.05% | SVB Leerink | → $6 | Initiates Coverage On | → Outperform |
| 11/11/2022 | 234.73% | Needham | $10 → $8 | Maintains | Buy |
| 06/30/2022 | 318.41% | Needham | $8 → $10 | Maintains | Buy |
| 05/25/2022 | 318.41% | Oppenheimer | → $10 | Initiates Coverage On | → Outperform |
| 03/29/2022 | 318.41% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 11/11/2021 | 234.73% | Needham | $10 → $8 | Maintains | Buy |
| 08/13/2021 | 318.41% | Needham | $12 → $10 | Maintains | Buy |
| 08/14/2020 | 276.57% | SVB Leerink | $8 → $9 | Maintains | Outperform |
| 07/13/2020 | 402.09% | Needham | $18 → $12 | Maintains | Buy |
| 06/03/2019 | 653.14% | Needham | → $18 | Initiates Coverage On | → Buy |
| 06/03/2019 | 527.62% | BMO Capital | → $15 | Initiates Coverage On | → Outperform |
| 06/03/2019 | 736.82% | Stifel | → $20 | Initiates Coverage On | → Buy |
What is the target price for Trevi Therapeutics (TRVI)?
The latest price target for Trevi Therapeutics (NASDAQ: TRVI) was reported by Needham on August 11, 2023. The analyst firm set a price target for $8.00 expecting TRVI to rise to within 12 months (a possible 234.73% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Trevi Therapeutics (TRVI)?
The latest analyst rating for Trevi Therapeutics (NASDAQ: TRVI) was provided by Needham, and Trevi Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Trevi Therapeutics (TRVI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trevi Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trevi Therapeutics was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
Is the Analyst Rating Trevi Therapeutics (TRVI) correct?
While ratings are subjective and will change, the latest Trevi Therapeutics (TRVI) rating was a reiterated with a price target of $0.00 to $8.00. The current price Trevi Therapeutics (TRVI) is trading at is $2.39, which is within the analyst's predicted range.